February 4, 2022
An unanticipated impact
Talk with anyone in pharma or MedTech and they will tell you the FDA continues to struggle with the backlog created by Covid. It took forever to get the Omnipod 5 approved, the G7 is still awaiting approval as are several other items in the diabetes world. It’s anyone’s guess how long it will take for the Libre 3 or tirzepatide to be approved as they have both been recently submitted to the FDA.
As frustrating as this may be there are some who are taking full advantage of this backlog. It’s no secret there are lots . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
